{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:43:52Z","timestamp":1793148232253,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jare.2024.12.026","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T19:48:51Z","timestamp":1734464931000},"page":"191-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A\/YTHDF3\/PDK1 axis under hypoxic conditions"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1525-5944","authenticated-orcid":false,"given":"Siyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingda","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanrun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5047-1601","authenticated-orcid":false,"given":"Song","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2024.12.026_b0005","doi-asserted-by":"crossref","unstructured":"Global Burden of Disease Cancer C, Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8(3):420-44.","DOI":"10.1001\/jamaoncol.2021.6987"},{"issue":"5","key":"10.1016\/j.jare.2024.12.026_b0010","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.ymthe.2021.04.009","article-title":"The evolving landscape of N(6)-methyladenosine modification in the tumor microenvironment","volume":"29","author":"Gu","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jare.2024.12.026_b0015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.semcancer.2019.12.003","article-title":"PD-L1 status in breast cancer: Current view and perspectives","volume":"72","author":"Vranic","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"10.1016\/j.jare.2024.12.026_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.42107","article-title":"Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial","volume":"6","author":"Takahashi","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.jare.2024.12.026_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002088","article-title":"Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck","volume":"9","author":"Zandberg","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jare.2024.12.026_b0030","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jare.2024.12.026_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100720","article-title":"Surmounting cancer drug resistance: New insights from the perspective of N(6)-methyladenosine RNA modification","volume":"53","author":"Li","year":"2020","journal-title":"Drug Resist Updat"},{"issue":"10","key":"10.1016\/j.jare.2024.12.026_b0040","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","article-title":"Reading, writing and erasing mRNA methylation","volume":"20","author":"Zaccara","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.jare.2024.12.026_b0045","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12916-021-02148-5","article-title":"m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer","volume":"19","author":"Zhang","year":"2021","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.jare.2024.12.026_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188873","article-title":"N6-methyladenosine RNA modification in PD-1\/PD-L1: Novel implications for immunotherapy","volume":"1878","author":"Luo","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"10.1016\/j.jare.2024.12.026_b0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41580-020-0227-y","article-title":"Cellular adaptation to hypoxia through hypoxia inducible factors and beyond","volume":"21","author":"Lee","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"24","key":"10.1016\/j.jare.2024.12.026_b0060","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-10-1360","article-title":"Hypoxia and hypoxia-inducible factors: master regulators of metastasis","volume":"16","author":"Lu","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jare.2024.12.026_b0065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1alpha pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1016\/j.jare.2024.12.026_b0070","doi-asserted-by":"crossref","first-page":"E1239","DOI":"10.1073\/pnas.1718197115","article-title":"Chemotherapy induces enrichment of CD47(+)\/CD73(+)\/PDL1(+) immune evasive triple-negative breast cancer cells","volume":"115","author":"Samanta","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.jare.2024.12.026_b0075","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150846","article-title":"Targeting HIF-1alpha abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues","volume":"132","author":"Bailey","year":"2022","journal-title":"J Clin Invest"},{"issue":"33","key":"10.1016\/j.jare.2024.12.026_b0080","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1038\/s41388-021-01916-0","article-title":"FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis","volume":"40","author":"Ruan","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jare.2024.12.026_b0085","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1038\/s41467-019-12651-2","article-title":"N(6)-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis","volume":"10","author":"Chen","year":"2019","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.jare.2024.12.026_b0090","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1038\/s41388-019-0733-6","article-title":"Base excision repair regulates PD-L1 expression in cancer cells","volume":"38","author":"Permata","year":"2019","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.jare.2024.12.026_b0095","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.cmet.2021.05.019","article-title":"Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1","volume":"33","author":"Wang","year":"2021","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.jare.2024.12.026_b0100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12943-019-1038-7","article-title":"METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma","volume":"18","author":"Li","year":"2019","journal-title":"Mol Cancer"},{"issue":"33","key":"10.1016\/j.jare.2024.12.026_b0105","article-title":"Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT","volume":"10","author":"Tang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.jare.2024.12.026_b0110","doi-asserted-by":"crossref","first-page":"10122","DOI":"10.1038\/s41598-018-28074-w","article-title":"Glucose starvation induces LKB1-AMPK-mediated MMP-9 expression in cancer cells","volume":"8","author":"Endo","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.jare.2024.12.026_b0115","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"49","key":"10.1016\/j.jare.2024.12.026_b0120","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1073\/pnas.1422015112","article-title":"Estrogen receptor-alpha directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer","volume":"112","author":"Yang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jare.2024.12.026_b0125","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ncb3330","article-title":"The ever-expanding role of HIF in tumour and stromal biology","volume":"18","author":"LaGory","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"41","key":"10.1016\/j.jare.2024.12.026_b0130","doi-asserted-by":"crossref","first-page":"E9640","DOI":"10.1073\/pnas.1809695115","article-title":"Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment","volume":"115","author":"Lan","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.jare.2024.12.026_b0135","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1172\/JCI95089","article-title":"ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis","volume":"128","author":"Chen","year":"2018","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jare.2024.12.026_b0140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-018-0034-6","article-title":"RNA N(6)-methyladenosine modification in cancers: current status and perspectives","volume":"28","author":"Deng","year":"2018","journal-title":"Cell Res"},{"issue":"3","key":"10.1016\/j.jare.2024.12.026_b0145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/cr.2017.15","article-title":"YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA","volume":"27","author":"Shi","year":"2017","journal-title":"Cell Res"},{"issue":"4","key":"10.1016\/j.jare.2024.12.026_b0150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.jare.2024.12.026_b0155","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12974-019-1561-x","article-title":"Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT\/STAT3 signaling","volume":"16","author":"Ryu","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"8","key":"10.1016\/j.jare.2024.12.026_b0160","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1158\/0008-5472.CAN-22-3407","article-title":"AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis","volume":"83","author":"Sun","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2024.12.026_b0165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2326-6066.CIR-18-0071","article-title":"PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3","volume":"7","author":"Ding","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.jare.2024.12.026_b0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"issue":"2","key":"10.1016\/j.jare.2024.12.026_b0175","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-inducible factors and the response to hypoxic stress","volume":"40","author":"Majmundar","year":"2010","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.jare.2024.12.026_b0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12943-019-1004-4","article-title":"RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3","volume":"18","author":"Niu","year":"2019","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.jare.2024.12.026_b0185","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1172\/JCI137552","article-title":"HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer","volume":"130","author":"de Heer","year":"2020","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jare.2024.12.026_b0190","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cmet.2017.10.005","article-title":"Advances in Hypoxia-Inducible Factor Biology","volume":"27","author":"Choudhry","year":"2018","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.jare.2024.12.026_b0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB Signaling: Navigating the Network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jare.2024.12.026_b0200","article-title":"Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma","volume":"36(36):JCO2018792549","author":"Hsieh","year":"2018","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.jare.2024.12.026_b0205","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/0008-5472.CAN-12-1345","article-title":"Tumor cells upregulate normoxic HIF-1alpha in response to doxorubicin","volume":"73","author":"Cao","year":"2013","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.jare.2024.12.026_b0210","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1158\/1078-0432.CCR-11-0666","article-title":"A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies","volume":"17","author":"Moroney","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jare.2024.12.026_b0215","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"10.1016\/j.jare.2024.12.026_b0220","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140436","article-title":"WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models","volume":"131","author":"Kishikawa","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jare.2024.12.026_b0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.jare.2024.12.026_b0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccell.2020.04.017","article-title":"Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion","volume":"38","author":"Su","year":"2020","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.jare.2024.12.026_b0235","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1021\/jm4000227","article-title":"Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1","volume":"56","author":"Medina","year":"2013","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.jare.2024.12.026_b0240","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1659092","article-title":"Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8(+) T cell function and survival through elevation of PD-L1","volume":"8","author":"Wang","year":"2019","journal-title":"Oncoimmunology"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123224006040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123224006040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T21:00:49Z","timestamp":1759784449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123224006040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":48,"alternative-id":["S2090123224006040"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2024.12.026","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A\/YTHDF3\/PDK1 axis under hypoxic conditions","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2024.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}